Clinical Trials

9 trials
RecentStart dateEnrollment
Completed × Temozolomide × Lymphoid × Clear all
NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1/2 Completed
41 enrolled
BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT00544284 2013-02-15

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

City of Hope Medical Center

Phase 1 Completed
25 enrolled
CNSLymphoidSarcoma

Astrocytoma, Brain Neoplasms, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Lymphoma, Medulloblastoma, Meningioma, Neoplasm Metastasis, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma